Kiniksa Pharmaceuticals International KNSA Cash Flow Statement (2017-2026)

NASDAQ KNSA
$79.23 +2.14 (+2.78%)
As of: Sep 9, 2026 · 2:47 PM EDT
Reported Financials

Kiniksa Pharmaceuticals International Quarterly Cash Flow Statement

Periods 37 quarters
Latest Jun 2026

Kiniksa Pharmaceuticals International reported cash from operations of $47.20M and free cash flow of $46.53M for the quarter ended Jun 2026, up 68.0% year over year. This cash flow statement covers 37 quarters of results from Jun 2017 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Cash Flow Statement Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Operating Activities
Net Income
-30.54M-44.08M-25.21M-19.98M224.09M88.53M-12.27M14.97M-13.86M-49.24M-17.70M-3.91M-12.69M-8.89M8.54M17.83M18.43M14.20M22.59M25.43M
Share-based CompensationStock Comp.
9.56M6.13M8.79M9.57M10.32M6.37M10.08M10.96M11.63M7.77M11.24M11.78M11.63M8.30M10.99M10.83M11.90M10.23M10.06M11.64M
Deferred Taxes
0.35M1.08M-19.44M10.29M-25.71M4.37M10.57M-3.64M0.65M2.99M2.64M4.23M6.06M4.52M2.66M
Cash from OperationsCash from Ops.
-28.51M-18.88M-36.85M-7.82M62.05M-11.58M-4.27M-3.74M16.99M4.33M3.99M5.17M-2.24M18.77M22.32M28.09M33.68M53.89M50.20M47.20M
Depreciation, Depletion & Amortization
Amortizatization of IntangiblesAmort. of Intangibles
-0.01M-0.05M-0.16M-0.08M0.12M0.20M1.06M1.15M-1.44M0.30M-0.30M0.19M0.49M-0.82M-0.26M0.84M-0.60M0.93M-1.30M-0.09M
Depreciation & Amortization (CF)Dep. & Amort.
0.66M0.67M0.66M0.65M0.49M0.60M0.60M0.60M0.60M0.54M0.47M0.43M0.40M0.40M0.34M0.36M0.38M0.47M0.47M0.47M
Change in Working Capital
Change in ReceivablesChange Receivables
0.67M0.69M25.45M-21.63M3.35M1.50M-5.24M17.23M-21.61M18.23M-5.27M4.46M4.44M16.84M-1.66M-8.15M19.83M-36.15M7.63M0.27M
Change in InventoryChange Inventory
-0.78M-1.93M9.55M6.69M-5.29M6.98M1.83M0.53M1.62M5.54M-3.84M7.58M-6.18M-2.32M-4.29M26.11M-6.79M13.50M18.25M-2.21M
Change in Account PayablesChange Payables
-2.54M0.25M1.51M-0.86M-1.05M6.43M-6.51M-0.74M0.36M7.23M-2.66M1.73M0.91M-6.28M0.06M6.93M-2.73M-4.12M22.27M-12.00M
Change in Accured ExpensesChange Accured Exp.
-2.46M10.04M4.08M-5.97M1.97M-3.79M-10.65M14.69M7.61M5.29M3.29M18.66M10.80M10.99M-3.60M13.10M8.37M19.63M-5.05M25.79M
Investing Activities
Capital ExpendituresCapex
0.78M2.23M-2.75M-0.16M-0.00M0.27M-3.27M0.09M-1.41M3.36M3.84M0.01M2.52M-2.04M0.07M0.14M3.40M0.16M0.66M
Sales of Property, Plant and EquipmentPP&E (Sale)
-0.01M0.01M
Change in Acquisitions & DivestmentsChange Acquisitions
47.90M10.00M7.50M63.80M36.40M20.10M15.00M73.70M40.83M45.98M61.88M42.44M48.13M87.48M44.03M30.61M84.08M40.78M145.66M36.70M
Cash from Investing ActivitiesCash from Investing
47.85M-50.04M-22.72M38.27M19.04M-42.66M-37.92M35.53M-12.28M-14.89M25.52M-46.80M-6.35M65.29M-51.54M-3.88M-62.76M-70.81M-31.92M-73.58M
Financing Activities
Other financing activitiesOther financing
2.68M1.21M0.99M0.57M0.57M1.29M0.51M0.58M1.66M0.96M3.99M1.14M9.40M2.72M3.18M12.74M16.25M8.58M6.39M17.58M
Cash from Financing ActivitiesCash from Financing
2.68M1.21M0.42M0.54M0.36M1.19M0.09M0.16M0.55M0.69M3.61M-0.18M6.69M2.14M2.77M10.70M11.90M7.66M6.07M12.11M
Change in Capital Stock
Net Shares Issued and RepurchasedNet Shares Issued
2.60M0.50M2.93M0.09M2.13M0.12M0.13M2.06M0.10M
Net Equity Issued and RepurchasedNet Equity Issued
Additional items
Change in Cash
22.02M-67.71M-59.15M30.98M81.45M-53.05M-42.10M31.95M5.26M-9.87M33.12M-41.81M-1.90M86.20M-26.45M34.91M-17.18M-9.26M24.36M-14.28M
Free Cash FlowFCF
-29.29M-21.11M-34.09M-7.66M62.05M-11.84M-1.00M-3.83M16.99M5.73M0.62M1.33M-2.25M16.25M24.37M28.02M33.53M50.49M50.04M46.53M
Net Cash FlowNCF
22.02M-67.71M-59.15M30.98M81.45M-53.05M-42.10M31.95M5.26M-9.87M33.12M-41.81M-1.90M86.20M-26.45M34.91M-17.18M-9.26M24.36M-14.28M